Andrew Hartley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1844040/publications.pdf

Version: 2024-02-01

28 papers 1,270 citations

840585 11 h-index 23 g-index

28 all docs

28 docs citations

28 times ranked

2203 citing authors

#	Article	IF	CITATIONS
1	Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial. Oral Oncology, 2021, 113, 105112.	0.8	16
2	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers, 2021, 13, 1413.	1.7	13
3	A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic. Clinical and Translational Radiation Oncology, 2021, 30, 50-59.	0.9	4
4	In reply to Iqbal et al Oral Oncology, 2021, 120, 105298.	0.8	O
5	Delayed contrast and multiparametric MRI for treatment response assessment in brain metastases following stereotactic radiosurgery. Neuro-Oncology, 2021, 23, iv22-iv23.	0.6	1
6	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	6.3	697
7	Does radiosurgery have a role for patients with colorectal brain metastases?. Neuro-Oncology, 2018, 20, i25-i26.	0.6	O
8	Revised Modelling of the Addition of Synchronous Chemotherapy to Radiotherapy in Squamous Cell Carcinoma of the Head and Neck—A Low α/β?. Medicines (Basel, Switzerland), 2018, 5, 54.	0.7	0
9	Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer. Medicines (Basel, Switzerland), 2018, 5, 65.	0.7	1
10	The Expanding Role of Radiosurgery for Brain Metastases. Medicines (Basel, Switzerland), 2018, 5, 90.	0.7	32
11	Dedifferentiated adenoid cystic carcinoma of the nasopharynx: a rare entity of head and neck cancer. BMJ Case Reports, 2016, 2016, bcr2016215889.	0.2	2
12	Does Dose to an Oral Mucosa Organ at Risk Predict the Duration of Grade 3 Mucositis after Intensity-modulated Radiotherapy for Oropharyngeal Cancer?. Clinical Oncology, 2016, 28, e216-e219.	0.6	9
13	Geographic variation in human papillomavirus–related oropharyngeal cancer: Data from 4 multinational randomized trials. Head and Neck, 2016, 38, E1863-9.	0.9	41
14	In Regard to Beitler etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 455-456.	0.4	1
15	A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. Clinical Cancer Research, 2014, 20, 5009-5022.	3.2	139
16	Can Protons or Altered Fractionation Decrease Neurotoxicity after Chemoradiation in Head and Neck Cancer?. Clinical Oncology, 2014, 26, 762-764.	0.6	3
17	Models of acute mucosal tolerance to radiotherapy alone applied to synchronous chemoradiation schedules in head and neck cancer. Tumor Biology, 2014, 35, 2017-2023.	0.8	7
18	Revising the Radiobiological Model of Synchronous Chemotherapy in Head-and-Neck Cancer: A New Analysis Examining Reduced Weighting of Accelerated Repopulation. International Journal of Radiation Oncology Biology Physics, 2013, 86, 157-163.	0.4	23

#	Article	IF	CITATIONS
19	Revised radiobiological modelling of the contribution of synchronous chemotherapy to the rate of grades 3–4 mucositis in head and neck cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 733-738.	0.9	5
20	Correlation of Currently Used Radiobiological Parameters with Local Control and Acute and Late Mucosal Toxicity in Randomised Studies of Altered Fractionation for Locally Advanced Head and Neck Cancer. Clinical Oncology, 2011, 23, 29-33.	0.6	20
21	Post-operative accelerated hypofractionated radiotherapy for adenoid cystic carcinoma. Journal of Radiotherapy in Practice, 2011, 10, 85-90.	0.2	0
22	Radiobiological Modelling of the Therapeutic Ratio for the Addition of Synchronous Chemotherapy to Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Oncology, 2010, 22, 125-130.	0.6	30
23	Modeling the Contribution of Synchronous Chemotherapy to the Rate of Grade 3 and 4 Mucositis in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2009, 75, 315.	0.4	3
24	Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer. Radiotherapy and Oncology, 2009, 93, 654.	0.3	11
25	Gap compensation during accelerated hypofractionated radiotherapy in head and neck cancer. Journal of Radiotherapy in Practice, 2008, 7, 31-38.	0.2	3
26	Hypofractionated Accelerated Radiotherapy With Concurrent Chemotherapy For Locally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1342-1351.	0.4	33
27	Cancer of the anal canal. Lancet Oncology, The, 2004, 5, 149-157.	5.1	172
28	To the Editor. Radiotherapy and Oncology, 2003, 68, 89-90.	0.3	4